| Literature DB >> 24839443 |
Kirstine Amris1, Eva Ejlersen Wæhrens2, Anders Jespersen1, Anders Stockmarr3, Robert Bennett4, Henning Bliddal1, Bente Danneskiold-Samsøe1.
Abstract
The clinical utility of tender point (TP) examination in patients reporting chronic widespread pain (CWP) is the subject of contemporary debate. The objective of this study was to assess the relationship between mechanical hyperalgesia assessed by manual TP examination and clinical disease severity. 271 women with CWP were recruited from a clinical setting. Data collection included patient-reported symptoms, health-related quality of life variables, and observation-based measures of functional ability, muscle strength, 6-minute walk, and pressure pain thresholds measured by cuff algometry. TP examination was conducted according to ACR-guidelines. Relationships between disease variables and TP count (TPC) were analyzed with logistic regression in a continuum model, allowing the TPC to depend on the included disease variables and two regression models carried out for a TPC threshold level, varying between 1 and 17. The threshold analyses indicated a TPC threshold at 8, above which a large number of disease variables became consistently significant explanatory factors, whereas none of the disease variables reached a significance level in the continuum model. These results support the premise that the presence of mechanical hyperalgesia influences symptomatology in CWP and that the severity of clinical expression is related to a threshold of TPs, rather than being part of a continuum.Entities:
Year: 2014 PMID: 24839443 PMCID: PMC4009262 DOI: 10.1155/2014/417596
Source DB: PubMed Journal: Int J Rheumatol ISSN: 1687-9260
Instruments classified according to the ICF core sets for CWP.
| ICF core sets for CWP | Instruments in this study |
|---|---|
| Body functions | |
| Emotional functions | GAD-10, MDI, SF-36, FIQ |
| Sensation of pain | FIQ, SF-36 |
| Exercise tolerance functions | Mob-T |
| Psychomotor functions | FIQ, SF-36 |
| Control of voluntary movement | AMPS motor |
| Energy and drive functions | Mob-T, SF-36, FIQ |
| Sleep functions | FIQ |
| Content of thoughts | CSQ |
| Muscle power functions | Grippit, LIDO Multi Joint |
| Attention function | AMPS process |
| Activity and participation | |
| Carrying out daily routines | AMPS, FIQ, SF-36 |
| Handling stress and other | CSQ |
| Family relationships | SF-36 |
| Remunerative employment | FIQ, BIQ |
| Intimate relationships | |
| Walking | 6-MW |
| Recreation and leisure | SF-36 |
| Solving problems | AMPS process, CSQ |
| Lifting and carrying objects | AMPS motor |
| Doing housework | AMPS, FIQ |
| Environmental factors | |
| Drugs | BIQ |
| Immediate family | BIQ |
| Health professionals | BIQ |
| Individual attitudes of immediate | |
| Social security services, systems, | BIQ |
| Individual attitudes of friends |
GAD-10: generalized anxiety disorder; MDI: major depression inventory; SF-36: short-form-36 health survey; FIQ: fibromyalgia impact questionnaire; CSQ: coping strategy questionnaire; AMPS: assessment of motor and process skills; 6-MW: 6-minute walk; Mob-T: mobility tiredness; BIQ: basic information questionnaire.
Demographic data and key variables classified according to the ICF model.
| Mean | SD | Range |
| |
|---|---|---|---|---|
| Demographics | ||||
| Age (years) | 45.5 | 9.66 | 20.4–71.5 | 271 |
| Symptom duration (months) | 122 | 102 | 6–540 | 227 |
| Body mass index (BMI) | 26.9 | 5.5 | 16.9–45.7 | 270 |
|
| ||||
| Never | Sometimes | Daily |
| |
|
| ||||
| Pain medication | ||||
| Weak analgesics | 3% | 63% | 34% | 237 |
| NSAID's | 39% | 43% | 18% | 230 |
| Opioids | 56% | 23% | 21% | 231 |
| Yes | No |
| ||
| Antidepressants | 31% | 69% | 237 | |
| Pain-related work interference | ||||
| Changes or permanent disability from usual working activity due to pain | 82% | 18% | 235 | |
| Applied for permanent disability pension at some stage | 25% | 75% | 231 | |
| Currently holding a position or enrolled in education | 21% | 239 | ||
| Currently on long-term sick leave | 25% | 239 | ||
| Currently receiving social benefits or socials services of some sort | 34% | 239 | ||
|
| ||||
| Mean | SD | Range |
| |
|
| ||||
| Body | ||||
| Muscle strength UE (PTQ extension) | 84.94 | 36.88 | 7–199 | 249 |
| Muscle strength UE (PTQ flexion) | 40.23 | 18.41 | 5–85 | 249 |
| Grip strength, max. | 174.96 | 82.24 | 8–408 | 258 |
| Vitality (SF-36) | 21.88 | 17.26 | 0–75 | 268 |
| Fatigue (FIQ) | 8.01 | 1.95 | 1.3–10 | 267 |
| Rest (FIQ) | 7.57 | 2.33 | 0–10 | 266 |
| Well-being (SF-36) | 55.62 | 20.61 | 0–100 | 268 |
| Well-being (FIQ) | 7.32 | 2.66 | 0–10 | 258 |
| Anxiety (FIQ) | 4.46 | 3.43 | 0–10 | 267 |
| Anxiety (GAD-10) | 19.17 | 9.78 | 1–50 | 268 |
| Depression (FIQ) | 3.81 | 3.42 | 0–10 | 268 |
| Depression (MDI) | 21.60 | 10.68 | 3–50 | 268 |
| Bodily pain (SF-36) | 24.07 | 15.03 | 0–84 | 268 |
| Pain intensity (FIQ) | 7.07 | 1.95 | 0–10 | 268 |
| Muscle stiffness (FIQ) | 6.25 | 2.75 | 0–10 | 265 |
| Tiredness mobility (Mob-T) | 1.68 | 1.61 | 0–6 | 257 |
| Pain detection threshold (PDT) | 12.16 | 7.52 | 0.3–46.2 | 229 |
| Pain tolerance threshold (PTT) | 31.65 | 14.73 | 9.2–86.7 | 229 |
| Activity and participation | ||||
| ADL ability motor (AMPS) | 1.07 | 0.50 | 0.4–2.82 | 257 |
| ADL ability process (AMPS) | 1.09 | 0.35 | 0.12–2.18 | 257 |
| Walking speed (6-MW) | 449.67 | 114.37 | 94.6–712.1 | 259 |
| Activity limitations (FIQ) | 5.24 | 2.22 | 0–9 | 267 |
| Physical functioning (SF-36) | 42.88 | 20.01 | 0–95 | 268 |
| Role physical (SF 36) | 9.71 | 21.03 | 0–100 | 267 |
| Role emotional (SF-36) | 45.12 | 43.30 | 0–100 | 263 |
| Social functioning (SF-36) | 48.04 | 26.47 | 0–100 | 268 |
| Days of sick leave pr. week (FIQ) | 1.12 | 1.68 | 0–6 | 70 |
| Work ability (FIQ) | 6.62 | 2.50 | 0–10 | 72 |
| Personal | ||||
| Catastrophizing (CSQ) | 15.91 | 8.35 | 0–36 | 266 |
| Perceived control over pain (CSQ) | 2.40 | 1.38 | 0–6 | 266 |
| Ability to decrease pain (CSQ) | 2.28 | 1.22 | 0–6 | 264 |
| Global measures | ||||
| FIQ total | 61.32 | 18.53 | 2.9–97.4 | 268 |
| SF-36 PCS | 26.95 | 6.68 | 8.8–50.7 | 268 |
| SF-36 MCS | 40.68 | 11.96 | 14.9–66.6 | 268 |
| General health (SF-36) | 31.60 | 18.15 | 0–97 | 267 |
GAD-10: generalized anxiety disorder; MDI: major depression inventory; SF-36: short-form-36 health survey; FIQ: fibromyalgia impact questionnaire; SF-36 PCS: SF-36 physical composite score; PTQ: peak torque; SF-36 MCS: SF-36 mental composite score; CSQ: coping strategy questionnaire; AMPS: assessment of motor and process skills; 6-MW: 6-minute walk; Mob-T: mobility tiredness.
Univariate/marginal model: significance of variables at a given tender point threshold with the pain response cutoff set at 1 at the tender point examination.
| Outcome variable | TP > 1 | TP > 2 | TP > 3 | TP > 4 | TP > 5 | TP > 6 | TP > 7 | TP > 8 | TP > 9 | TP > 10 | TP > 11 | TP > 12 | TP > 13 | TP > 14 | TP > 15 | TP > 16 | TP > 17 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Body | |||||||||||||||||
| Muscle strength UE (PTQ ext.) | ∗ | ||||||||||||||||
| Muscle strength UE (PTQ flex.) | ∗ | ∗∗ | |||||||||||||||
| Grip strength, max. | ∗ | ∗∗ | ∗∗ | ||||||||||||||
| Vitality (SF-36) | ∗ | ||||||||||||||||
| Fatigue (FIQ) | ∗ | ||||||||||||||||
| Rest (FIQ) | ∗ | ∗ | |||||||||||||||
| Well-being (SF-36) | ∗ | ||||||||||||||||
| Well-being (FIQ) | |||||||||||||||||
| Anxiety (FIQ) | |||||||||||||||||
| Anxiety (GAD-10) | |||||||||||||||||
| Depression (FIQ) | |||||||||||||||||
| Depression (MDI) | |||||||||||||||||
| Bodily pain (SF-36) | ∗ | ||||||||||||||||
| Pain intensity (FIQ) | ∗ | ||||||||||||||||
| Muscle stiffness (FIQ) | ∗ | ||||||||||||||||
| Tiredness mobility (Mob-T) | ∗ | ∗ | |||||||||||||||
| Pain detection threshold (PDT) | ∗ | ∗ | ∗ | ∗∗ | ∗∗ | ||||||||||||
| Pain tolerance threshold (PTT) | ∗ | ∗ | ∗ | ∗∗ | ∗∗∗ | ∗∗ | |||||||||||
| Activity and participation | |||||||||||||||||
| ADL ability motor (AMPS) | ∗ | ∗ | |||||||||||||||
| ADL ability process (AMPS) | |||||||||||||||||
| Walking speed (6-MW) | ∗ | ||||||||||||||||
| Activity limitations (FIQ) | ∗ | ∗ | ∗ | ∗ | |||||||||||||
| Physical functioning (SF-36) | |||||||||||||||||
| Role physical (SF 36) | |||||||||||||||||
| Role emotional (SF-36) | |||||||||||||||||
| Social functioning (SF-36) | |||||||||||||||||
| Work interference (BIQ) | ∗ | ∗ | ∗ | ∗ | |||||||||||||
| Personal | |||||||||||||||||
| Catastrophizing (CSQ) | |||||||||||||||||
| Perceived control over pain (CSQ) | |||||||||||||||||
| Ability to decrease pain (CSQ) | |||||||||||||||||
| Analgesics yes/no | |||||||||||||||||
| NSAID | |||||||||||||||||
| Opioids | |||||||||||||||||
| Antidepressants | |||||||||||||||||
| Global measures | |||||||||||||||||
| FIQ total | |||||||||||||||||
| SF-36 PCS | ∗ | ∗ | |||||||||||||||
| SF-36 MCS | |||||||||||||||||
| General health (SF-36) |
*P < 0.05; **P < 0.01; ***P < 0.001; GAD-10: generalized anxiety disorder; MDI: major depression inventory; SF-36: short-form-36 health survey; FIQ: fibromyalgia impact questionnaire; SF-36 PCS: SF-36 physical composite score; PTQ flex.: peak torque flexion; SF-36 MCS: SF-36 mental composite score; PTQ ext.: peak torque extension; CSQ: coping strategy questionnaire; PDT: pain detection threshold; AMPS: assessment of motor and process skills; PTT: pain tolerance threshold; 6-MW: 6-minute walk; BIQ: basic information questionnaire.
Univariate/marginal model: significance of variables at a given tender point threshold with the pain response cutoff set at 2 at the tender point examination.
| Outcome variable | TP > 1 | TP > 2 | TP > 3 | TP > 4 | TP > 5 | TP > 6 | TP > 7 | TP > 8 | TP > 9 | TP > 10 | TP > 11 | TP > 12 | TP > 13 | TP > 14 | TP > 15 | TP > 16 | TP > 17 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Body | |||||||||||||||||
| Muscle strength UE (PTQ extension) | ∗ | ∗ | ∗ | ∗ | ∗ | ∗∗∗ | ∗∗∗ | ∗∗∗ | ∗∗∗ | ||||||||
| Muscle strength UE (PTQ flexion) | ∗ | ∗ | ∗ | ∗∗ | ∗∗ | ∗∗ | ∗∗∗ | ∗∗∗ | ∗∗∗ | ∗∗∗ | |||||||
| Grip strength, max. | ∗∗∗ | ∗ | ∗∗ | ∗ | ∗ | ∗ | |||||||||||
| Vitality (SF-36) | ∗ | ∗∗ | ∗∗ | ∗∗ | ∗∗ | ∗∗ | ∗∗ | ∗ | ∗ | ||||||||
| Fatigue (FIQ) | ∗ | ∗∗ | ∗∗∗ | ∗∗∗ | ∗∗∗ | ∗∗∗ | ∗∗∗ | ∗∗ | ∗ | ∗ | |||||||
| Rest (FIQ) | ∗∗ | ∗∗ | ∗∗∗ | ∗∗∗ | ∗∗∗ | ∗∗∗ | ∗∗∗ | ∗∗∗ | ∗∗ | ∗∗ | |||||||
| Well-being (SF-36) | ∗ | ∗ | ∗ | ||||||||||||||
| Well-being (FIQ) | ∗ | ∗ | ∗ | ∗∗ | ∗∗ | ∗ | ∗∗ | ||||||||||
| Anxiety (FIQ) | |||||||||||||||||
| Anxiety (GAD-10) | ∗ | ∗ | ∗ | ||||||||||||||
| Depression (FIQ) | |||||||||||||||||
| Depression (MDI) | ∗ | ∗ | |||||||||||||||
| Bodily pain (SF-36) | ∗ | ∗ | ∗∗ | ∗∗∗ | ∗∗ | ∗∗ | ∗∗ | ∗∗∗ | ∗∗∗ | ∗∗∗ | ∗∗∗ | ||||||
| Pain intensity (FIQ) | ∗ | ∗∗ | ∗∗∗ | ∗∗ | ∗∗ | ∗∗ | ∗∗∗ | ∗∗∗ | ∗∗ | ∗∗ | |||||||
| Muscle stiffness (FIQ) | ∗ | ∗∗ | ∗ | ∗∗ | ∗∗∗ | ∗∗∗ | ∗∗∗ | ∗∗∗ | ∗∗ | ∗∗ | ∗∗ | ∗ | ∗ | ||||
| Tiredness mobility (Mob-T) | ∗ | ∗ | ∗ | ∗ | ∗∗ | ∗∗ | ∗∗ | ∗ | ∗ | ∗ | ∗ | ∗∗ | ∗∗ | ||||
| Pain detection threshold (PDT) | ∗ | ∗ | ∗∗∗ | ∗∗∗ | ∗∗∗ | ∗∗∗ | ∗∗∗ | ∗∗∗ | ∗∗ | ∗∗ | |||||||
| Pain tolerance threshold (PTT) | ∗ | ∗∗ | ∗∗∗ | ∗∗∗ | ∗∗ | ∗∗∗ | ∗∗∗ | ∗∗∗ | ∗∗∗ | ∗∗ | |||||||
| Activity and participation | |||||||||||||||||
| ADL ability motor (AMPS) | ∗ | ∗∗ | ∗ | ∗ | ∗∗ | ∗∗ | ∗∗ | ∗∗∗ | ∗∗∗ | ∗∗∗ | ∗∗ | ∗∗ | ∗∗∗ | ∗∗∗ | ∗ | ∗ | |
| ADL ability process (AMPS) | ∗ | ∗ | |||||||||||||||
| Walking speed (6-MW) | ∗ | ∗∗ | ∗∗ | ∗ | ∗ | ∗ | ∗∗ | ∗ | ∗∗ | ∗∗ | ∗∗ | ∗ | |||||
| Activity limitations (FIQ) | ∗ | ∗∗ | ∗∗∗ | ∗∗ | ∗∗∗ | ∗∗ | ∗∗∗ | ∗∗ | ∗∗ | ∗∗ | ∗ | ||||||
| Physical functioning (SF-36) | ∗ | ∗∗ | ∗ | ∗ | ∗∗ | ∗∗∗ | ∗∗ | ∗∗ | ∗∗ | ∗∗ | |||||||
| Role physical (SF 36) | |||||||||||||||||
| Role emotional (SF-36) | |||||||||||||||||
| Social functioning (SF-36) | ∗ | ∗ | |||||||||||||||
| Work interference (BIQ) | ∗ | ∗ | |||||||||||||||
| Personal | |||||||||||||||||
| Catastrophizing (CSQ) | |||||||||||||||||
| Perceived control over pain (CSQ) | |||||||||||||||||
| Ability to decrease pain (CSQ) | ∗ | ||||||||||||||||
| Analgesics yes/no | ∗∗ | ∗ | |||||||||||||||
| NSAID | ∗ | ∗ | ∗ | ||||||||||||||
| Opioids | ∗ | ||||||||||||||||
| Antidepressants | ∗ | ∗ | |||||||||||||||
| Global measures | |||||||||||||||||
| FIQ total | ∗ | ∗∗ | ∗∗ | ∗∗ | ∗∗ | ∗∗ | ∗∗ | ∗∗ | ∗ | ∗∗ | |||||||
| SF-36 PCS | ∗ | ∗∗ | ∗ | ∗∗ | ∗∗ | ∗∗∗ | ∗∗∗ | ∗∗∗ | ∗∗∗ | ∗∗∗ | |||||||
| SF-36 MCS | ∗ | ||||||||||||||||
| General health (SF-36) |
*P < 0.05; **P < 0.01; ***P < 0.001; GAD-10: generalized anxiety disorder; MDI: major depression inventory; SF-36: short-form-36 health survey; FIQ: fibromyalgia impact questionnaire; SF-36 PCS: SF-36 physical composite score; PTQ flex.: peak torque flexion; SF-36 MCS: SF-36 mental composite score; PTQ ext.: peak torque extension; CSQ: coping strategy questionnaire; PDT: pain detection threshold; AMPS: assessment of motor and process skills; PTT: pain tolerance threshold; 6-MW: 6-minute walk; BIQ: basic information questionnaire.
Figure 1Number of significant covariates versus tender point count (TPC) thresholds, varying between 1 and 17 and with the pain response cutoff set at 2 at the tender point examination. Analyzed in the univariate/marginal model a large number of variables linked to pain and pain-related functional interference (summarized in Table 4) appeared as consistently significant explanatory factors from a TPC threshold at 8, indicating a perturbation of clinical disease severity at this threshold.
Multivariate/full model: significance of variables at a given tender point threshold with the pain response cutoff set at 2 at the tender point examination.
| Outcome variable | TP > 6 | TP > 7 | TP > 8 | TP > 9 | TP > 10 | TP > 11 | TP > 12 | TP > 13 | TP > 14 | TP > 15 | TP > 16 | TP > 17 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Body | ||||||||||||
| Muscle strength UE (PTQ extension) | ||||||||||||
| Muscle strength UE (PTQ flexion) | ∗ | ∗∗ | ∗ | ∗ | ||||||||
| Grip strength, max. | ||||||||||||
| Vitality (SF-36) | ∗ | |||||||||||
| Fatigue (FIQ) | ||||||||||||
| Rest (FIQ) | ∗ | ∗∗ | ∗ | ∗ | ∗∗∗ | ∗∗ | ||||||
| Well-being (SF-36) | ∗∗ | |||||||||||
| Well-being (FIQ) | ∗ | ∗∗ | ∗ | |||||||||
| Anxiety (FIQ) | ∗ | |||||||||||
| Anxiety (GAD-10) | ||||||||||||
| Depression (FIQ) | ∗∗ | ∗ | ∗ | ∗∗∗ | ∗∗∗ | |||||||
| Depression (MDI) | ∗ | ∗∗ | ||||||||||
| Bodily pain (SF-36) | ∗ | |||||||||||
| Pain intensity (FIQ) | ||||||||||||
| Muscle stiffness (FIQ) | ∗ | ∗∗ | ∗ | ∗∗ | ∗∗ | |||||||
| Tiredness mobility (Mob-T) | ∗∗ | ∗ | ||||||||||
| Pain detection threshold (PDT) | ∗∗ | ∗∗ | ∗∗∗ | ∗∗∗ | ∗∗ | |||||||
| Pain tolerance threshold (PTT) | ∗∗∗ | ∗∗∗ | ∗∗∗ | |||||||||
| Activity and participation | ||||||||||||
| ADL ability motor (AMPS) | ∗∗ | ∗∗∗ | ∗∗ | ∗∗∗ | ∗∗ | ∗ | ||||||
| ADL ability process (AMPS) | ||||||||||||
| Walking speed (6-MW) | ||||||||||||
| Activity limitations (FIQ) | ∗ | |||||||||||
| Physical functioning (SF-36) | ∗ | ∗∗∗ | ||||||||||
| Role physical (SF 36) | ∗ | ∗∗ | ||||||||||
| Role emotional (SF-36) | ∗∗∗ | |||||||||||
| Social functioning (SF-36) | ∗∗ | ∗∗ | ||||||||||
| Work interference (BIQ) | ∗ | ∗∗ | ∗∗∗ | ∗∗ | ||||||||
| Personal | ||||||||||||
| Catastrophizing (CSQ) | ||||||||||||
| Perceived control over pain (CSQ) | ||||||||||||
| Ability to decrease pain (CSQ) | ∗∗ | ∗ | ||||||||||
| Analgesics yes/no | ||||||||||||
| NSAID | ∗ | ∗∗ | ∗ | |||||||||
| Opioids | ||||||||||||
| Antidepressants | ∗ | |||||||||||
| Global measures | ||||||||||||
| FIQ total | ∗∗∗ | ∗∗∗ | ∗∗ | ∗∗ | ||||||||
| SF-36 PCS | ∗∗ | |||||||||||
| SF-36 MCS | ||||||||||||
| General health (SF-36) |
*P < 0.05; **P < 0.01; ***P < 0.001; GAD-10: generalized anxiety disorder; MDI: major depression inventory; SF-36: short-form-36 health survey; FIQ: fibromyalgia impact questionnaire; SF-36 PCS: SF-36 physical composite score; PTQ flex.: peak torque flexion; SF-36 MCS: SF-36 mental composite score; PTQ ext.: peak torque extension; CSQ: coping strategy questionnaire; PDT: pain detection threshold; AMPS: assessment of motor and process skills; PTT: pain tolerance threshold; 6-MW: 6-minute walk; BIQ: basic information questionnaire.
Variables classified according to the ICF model. Differences between groups at a tender point threshold level at 8 with the pain response cutoff set at 2 at the tender point examination.
| Outcome variable | TPC: 0–8 | TPC: 9–18 |
| ||
|---|---|---|---|---|---|
| Mean (SD) | Range | Mean (SD) | Range | ||
| Body | |||||
| Muscle strength UE (PTQ extension) | 96.8 (30.6) | 38–160 | 83.0 (37.5) | 7–199 |
|
| Muscle strength UE (PTQ flexion) | 46.6 (17.9) | 18–85 | 39.2 (18.3) | 5–84 |
|
| Grip strength, max. | 192.5 (63.61) | 76–304 | 172.2 (84.6) | 8–408 | 0.176 |
| Vitality (SF-36) | 26.3 (16.9) | 0–70 | 21.2 (17.2) | 0–75 | 0.105 |
| Fatigue (FIQ) | 7.3 (2.2) | 1.3–10 | 8.1 (1.9) | 1.4–10 |
|
| Rest (FIQ) | 6.5 (2.5) | 0.6–10 | 7.7 (2.3) | 0.1–10 |
|
| Well-being (SF-36) | 55.2 (20.4) | 20–92 | 55.7 (20.7) | 0–100 | 0.904 |
| Well-being (FIQ) | 6.6 (2.6) | 0–10 | 7.5 (2.7) | 0–10 | 0.079 |
| Anxiety (FIQ) | 3.9 (3.6) | 0–10 | 4.5 (3.4) | 0–10 | 0.328 |
| Anxiety (GAD-10) | 17.3 (9.4) | 3–42 | 19.5 (9.8) | 1–50 | 0.217 |
| Depression (FIQ) | 4.3 (3.4) | 0–10 | 3.7 (3.4) | 0–10 | 0.348 |
| Depression (MDI) | 21.1 (10.7) | 5–45 | 21.7 (10.7) | 3–50 | 0.763 |
| Bodily pain (SF-36) | 29.1 (12.3) | 0–60 | 22.3 (15.3) | 0–84 |
|
| Pain intensity (FIQ) | 6.4 (1.9) | 1.5–9.5 | 7.2 (1.9) | 0–10 |
|
| Muscle stiffness (FIQ) | 4.8 (2.9) | 0–9.8 | 6.5 (2.7) | 0–10 |
|
| Tiredness mobility (Mob-T) | 2.4 (1.8) | 0–6 | 1.5 (1.6) | 0–6 |
|
| Pain detection threshold (PDT) | 15.0 (8.4) | 4.2–46.2 | 11.7 (7.2) | 0.7–42.5 |
|
| Pain tolerance threshold (PTT) | 37.1 (14.2) | 12.3–72.8 | 30.7 (14.6) | 9.2–86.7 |
|
| Activity and participation | |||||
| ADL ability motor (AMPS) | 1.29 (0.49) | 0.11–2.45 | 1.04 (0.49) | 0.04–2.82 |
|
| ADL ability process (AMPS) | 1.16 (0.37) | 0.53–1.86 | 1.08 (0.34) | 0.12–2.18 | 0.204 |
| Walking speed (6-MW) | 487.5 (127.3) | 142–672 | 443.8 (111.4) | 95–712 |
|
| Activity limitations (FIQ) | 4.2 (2.3) | 0–8.7 | 5.4 (2.2) | 0–9 |
|
| Physical functioning (SF-36) | 50.8 (19.3) | 10–85 | 41.7 (19.9) | 0–95 |
|
| Role physical (SF 36) | 8.6 (20.14) | 0–75 | 9.9 (21.2) | 0–100 | 0.733 |
| Role emotional (SF-36) | 41.2 (41.9) | 0–100 | 45.7 (43.6) | 0–100 | 0.57 |
| Social functioning (SF-36) | 52.1 (27.0) | 12.5–100 | 47.4 (26.4) | 0–100 | 0.326 |
| Days of sick leave pr. week (FIQ) | 0.89 (1.3) | 0–2.9 | 1.2 (1.7) | 0–5.7 | 0.685 |
| Work ability (FIQ) | 5.7 (2.8) | 1.4–8.2 | 6.8 (2.5) | 0–10 | 0.218 |
| Personal | |||||
| Catastrophizing (CSQ) | 15.3 (8.3) | 0–33 | 16.0 (8.4) | 0–36 | 0.628 |
| Perceived control over pain (CSQ) | 2.6 (1.4) | 0–5 | 2.4 (1.4) | 0–6 | 0.354 |
| Ability to decrease pain (CSQ) | 2.5 (1.4) | 0–5 | 2.3 (1.2) | 0–6 | 0.284 |
| Global measures | |||||
| FIQ total | 54.4 (18.59) | 14.8–92.1 | 62.3 (18.4) | 2.9–97.4 |
|
| SF-36 PCS | 29.7 (7.0) | 15.8–43.8 | 26.5 (6.6) | 8.8–50.7 |
|
| SF-36 MCS | 40.1 (12.6) | 20.4–64.3 | 40.8 (11.9) | 14.9–66.6 | 0.773 |
| General health (SF-36) | 34.1 (15.6) | 5–77 | 31.2 (18.5) | 0–97 | 0.4 |
GAD-10: generalized anxiety disorder; MDI: major depression inventory; SF-36: short-form-36 health survey; FIQ: fibromyalgia impact questionnaire; SF-36 PCS: SF-36 physical composite score; PTQ: peak torque; SF-36 MCS: SF-36 mental composite score; CSQ: coping strategy questionnaire; AMPS: assessment of motor and process skills; Mob-T: mobility tiredness; 6-MW: 6-minute walk.